Back

Digital AI lifestyle support improves blood pressure control on top of standard dual antihypertensive therapy

30 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in hypertension Lifestyle Modification ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Bekzod Rozibaev

Tashkent (Uzbekistan)

5 More presentations in this session

Presentation thumbnail
Baseline characteristics and antihypertensive patterns in Finnish patients with hypertension and kidney disease
Professor T. Niiranen (Turku, FI)
Abstract Slides
Presentation thumbnail
Artificial intelligence-assisted personalised dose titration for hypertension: safety and feasibility results of the CURATE.AI pilot randomised controlled trial
Doctor X. Tadeo (Singapore, SG)
Abstract Slides
Presentation thumbnail
Renal function and hyperkalemia with first-line eplerenone in obese patients with hypertension: randomized safety data from the HEBRO trial
Doctor P. Iliakis (Athens, GR)
Abstract Slides
Presentation thumbnail
Predicting individual blood pressure response to additional antihypertensive treatment: a prototype decision support tool for healthcare professionals in the community
Associate Professor A. Gupta (London, GB)
Abstract Slides
Presentation thumbnail
Modifiable risk factors and 5-year and lifetime risks of cardiovascular disease among 0.5 million hypertensive patients in primary care
Doctor J. Wang (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Pharmacotherapy in hypertension

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Randomized controlled pilot study comparing different digital solutions for the management of hypertensive patients: the HSMonitor-IT study.
5 April 2025
thumbnail
Congress Presentation
Optimizing weight loss with AI: a randomized trial of dietary supplement prescriptions in obese patients
5 April 2025
thumbnail
Congress Presentation
Nature-AGT: Using Causal AI to estimate the optimal timing of lowering SBP with an siRNA directed against angiotensinogen to reduce the lifetime risk of cardiovascular events
31 August 2024
thumbnail
Congress Presentation
The effect of a novel lifestyle intervention on autonomic and haemodynamic function in individuals with hypertrophic cardiomyopathy
14 April 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources